GET DAILY SIGNALSLifeStance Health (LFST) Advances +15% Over the Last 30 Days
Key Takeaways
- LifeStance Health (LFST) gained roughly 15% over the past 30 days, building on a multi-month uptrend that has taken shares well above their mid-2026 lows.
- The advance follows a solid second-quarter 2026 report showing revenue up 26% and adjusted EBITDA up 94% year over year, with full-year guidance raised.
- Over the last three months, the stock has climbed about 37% as the company moves toward sustained profitability and wider margins.
- Growth is supported by a larger clinician base, higher visit volumes, and faster expansion in specialty services such as TMS and Spravato.
- A $100 million share repurchase program and higher analyst price targets have helped sustain positive sentiment.
- Investors are focused on the third-quarter 2026 earnings release, which aligns with management’s revenue guidance of $420 million to $440 million.
Company Background and Market Context
LifeStance Health Group, Inc. ranks among the largest outpatient mental healthcare providers in the United States. Founded in 2017 and based in Scottsdale, Arizona, the company offers both virtual and in-person care for children, adolescents, and adults through psychiatrists, advanced practice nurses, psychologists, and therapists. It now employs more than 8,500 clinicians across 33 states and over 550 centers.
The model blends a national brand and centralized technology platform with local clinical practices, covering therapy and psychiatry services. I follow LFST because of its scale in a structurally underserved behavioral health market, its growth through tuck-in acquisitions and de novo openings, and its progress toward consistent profitability via margin expansion and productivity gains. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Stock Price Moves: 30 Days and the Quarter
Over the last 30 days, LFST rose approximately 15%, advancing from a closing price near $12.22 in early October to roughly $14.07 in recent trading. The path was not linear—shares dipped to the mid-$11 range in mid-October before a steady climb carried them to multi-month highs heading into early November.
The three-month trend has been stronger still. From a closing level near $10.26 in early August, the stock has risen about 37%, reflecting a sustained re-rating as better-than-expected results and raised guidance took hold. This quarterly advance continues the recovery from earlier depressed levels in the year.
Drivers Behind the 30-Day Advance
The recent 30-day move reflects a mix of fundamental momentum and investor positioning. Second-quarter 2026 results, released in early August, showed revenue of $435.4 million, up 26% year over year, with adjusted EBITDA jumping 94% to $66 million and net income turning positive. Management also lifted full-year 2026 guidance to revenue of $1.685 billion to $1.725 billion and adjusted EBITDA of $215 million to $235 million.
These figures set a constructive tone that carried through October. Sentiment was further supported by a growing clinician base, rising visit volumes, expansion of higher-margin specialty services, and the $100 million share repurchase program. As the third-quarter 2026 earnings date neared, buying interest picked up, reflecting expectations that LifeStance would maintain double-digit revenue growth and margin improvement. I also checked this using Tickeron’s AI Trend Prediction Engine to gauge momentum.
Quarterly Performance and Operational Inflection
Over the last three months, LFST’s roughly 37% gain has been driven by a broader story of operational progress. The company has posted consecutive quarters of strong revenue growth and margin expansion, shifting from modest profitability toward a more consistent earnings profile. Rising revenue per visit, improved payer contracting, and higher clinician productivity have lifted Center Margin and adjusted EBITDA.
Strategic moves have reinforced the trend. LifeStance resumed disciplined tuck-in acquisitions to enter new markets, expanded treatment-resistant depression services including TMS and Spravato, and continued deploying AI-enabled and workflow-automation tools to improve scheduling, documentation, and revenue cycle management. Higher analyst price targets and the share repurchase authorization added further support over the quarter.
Key Factors to Watch Going Forward
Looking ahead, the most immediate catalyst remains the third-quarter 2026 earnings report, which follows management’s revenue guidance of $420 million to $440 million. Investors will assess whether revenue growth, clinician productivity, and margin expansion continue at recent rates, along with any update to full-year guidance.
Other items to monitor include the pace of clinician hiring and retention, revenue per visit trends from payer negotiations, and the rollout of specialty services such as TMS and Spravato. The planned transition to a new electronic health record system in 2027, tuck-in acquisition activity, and broader macroeconomic and regulatory developments in behavioral health could also play a role. As with any investment, outcomes depend on execution and market conditions, and past performance does not guarantee future results.
My Take on Tickeron’s AI Daily Buy/Sell Signals
In my own research process, I often review Tickeron’s AI Daily Buy/Sell Signals to cross-check short-term sentiment around names like LFST. The tool surfaces data-driven signals across thousands of tickers, which helps me compare my fundamental view with automated pattern recognition and momentum indicators. It serves as one more input rather than a standalone decision maker, but it adds useful context when earnings or guidance updates are approaching.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LFST in upward trend: price rose above 50-day moving average on October 22, 2026
LFST moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend. In 26 of 31 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on LFST as a result. In 72 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for LFST just turned positive on October 22, 2026. Looking at past instances where LFST's MACD turned positive, the stock continued to rise in 39 of 51 cases over the following month. The odds of a continued upward trend are 76%.
The 10-day moving average for LFST crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Following a +4.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where LFST advanced for three days, in 226 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Aroon Indicator entered an Uptrend today. In 179 of 246 cases where LFST Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Bearish Trend Analysis
The 10-day RSI Indicator for LFST moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In 29 of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at 74%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LFST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
LFST broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. LFST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 86 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.441) is normal, around the industry mean (204.016). P/E Ratio (95.500) is within average values for comparable stocks, (19.314). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.094) among similar stocks. P/S Ratio (3.182) is also within normal values, averaging (2.688).
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 98 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LFST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement
Advertisement